Showing results (871-880 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|June 30, 2022
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trialAbhishek Abhishek, Rosemary J Boyton, Nicholas Peckham, et al.
The Lancet. Respiratory Medicine|December 17, 2022
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard carePallav L Shah, Christopher M Orton, Beatriz Grinsztejn, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
The Lancet. Respiratory Medicine|July 1, 2022
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysisMarius M Hoeper, Krit Dwivedi, Christine Pausch, et al.
The Lancet. Respiratory Medicine|June 20, 2021
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trialJurjan Aman, Erik Duijvelaar, Liza Botros, et al.
The Lancet. Respiratory Medicine|July 2, 2021
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE studySteven D Nathan, Aaron Waxman, Sudarshan Rajagopal, et al.
The Lancet. Respiratory Medicine|July 13, 2021
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trialSarah Diver, Latifa Khalfaoui, Claire Emson, et al.
The Lancet. Respiratory Medicine|June 14, 2021
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Michael Schreinlechner, Nikolay Sappler, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trialAndrei M Darie, Nina Khanna, Kathleen Jahn, et al.
The Lancet. Respiratory Medicine|July 9, 2019
Corrections
Pageof 104